Sinopharm Group Co. Ltd. (HKG:1099)

Market Cap	46.37B -19.0%
Revenue (ttm)	660.27B -0.7%
Net Income	8.19B +4.1%
EPS	2.62 +4.0%
Shares Out	3.12B
PE Ratio	5.67
Forward PE	5.17
Dividend	0.80 (5.42%)
Ex-Dividend Date	Jun 23, 2026

Volume	6,182,766
Open	14.75
Previous Close	14.74
Day's Range	14.64 - 14.92
52-Week Range	14.60 - 22.34
Beta	0.44
Analysts	Buy
Price Target	21.10 (+41.99%)
Est. Earnings	Oct 30, 2026

About Sinopharm Group

Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are organized across four main divisions. Its Pharmaceutical Distribution segment supplies pharmaceutical goods to a wide range of clients, including hospitals, fellow distributors, retail pharmacies, and clinics. This division additionally offers extensive distribution, logistics, and value-added support ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2003
• Employees: 90,447
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1099

Financial Performance

In 2025, Sinopharm Group's revenue was 575.17 billion, a decrease of -1.60% compared to the previous year's 584.51 billion. Earnings were 7.16 billion, an increase of 1.50%.

Financial numbers in CNY

Analyst Summary

According to 15 analysts, the average rating for 1099 stock is "Buy." The 12-month stock price target is $21.10, which is an increase of 41.99% from the latest price.

Price Target

$21.10

(41.99% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 1, 2026

Data Sources Report a data error